Anthera Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported total revenues of $0 against $1,918,000 a year ago. Loss from operations was $14,579,000 against $7,390,000 a year ago. Net loss applicable to common stockholders was $15,092,000 or $0.36 basic and diluted per share against $7,339,000 or $0.18 basic and diluted per share a year ago. The increase in net loss is mainly attributable to the increase in manufacturing expense for Sollpura™ and clinical study expense for both Sollpura™ and blisibimod in 2016. For the year, the company reported total revenues of $145,000 against $3,185,000 a year ago. Loss from operations was $57,177,000 against $35,243,000 a year ago. Net loss applicable to common stockholders was $66,437,000 or $1.61 basic and diluted per share against $35,220,000 or $0.99 basic and diluted per share a year ago. The increase in net loss is mainly attributable to the increase in manufacturing expense for Sollpura™ and clinical study expense for both Sollpura™ and blisibimod in 2016.